Male breast cancer: Clinico-pathological features, immunocytochemical characteristics and prognosis

D. M. Bruce*, S. D. Heys, S. Payne, I. D. Miller, O. Eremin

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

47 Citations (Scopus)


A series of 30 cases of male breast cancer in the North-East of Scotland is reviewed. The aims of the study were to document clinico-pathological and immunocytochemical features (available for 25) of these patients and to establish ,which factors could predict prognosis. Tumours were studied for the expression of oestrogen receptors (ERs), the oestrogen-dependent proteins pS2 and cathepsin D, the oncoprotein products of c-erb-B2 and the p53 tumour-suppressor-gene derived protein. Clinico-pathological features documented were in agreement with those reported by other authors. The overall 5-year survival was 53%. Tumour grade and lymph-node status influenced prognosis. In this series, 64% of the tumours expressed ERs, 50% pS2, 46% cathepsin D, 42% the c-erb-B2 transmembrane oncoprotein and 54% p53. In contrast to female breast cancer, the presence of either substantial amounts of ERs or the oestrogen-dependent protein pS2 correlated with poorer prognosis in males. This correlation has not previously been documented.

Original languageEnglish
Pages (from-to)42-46
Number of pages5
JournalEuropean Journal of Surgical Oncology
Issue number1
Publication statusPublished - 1 Feb 1996


  • Breast neoplasms
  • Immunohistochemistry
  • Male


Dive into the research topics of 'Male breast cancer: Clinico-pathological features, immunocytochemical characteristics and prognosis'. Together they form a unique fingerprint.

Cite this